Agenda
FOOD AND DRUG ADMINISTRATION
TRANSMISSIBLE
SPONGIFORM ENCEPHALOPATHIES
ADVISORY
COMMITTEE
February 8, 2005
Hilton Hotel
8727
Colesville Road
Silver
Spring, MD
8:00 a.m. Administrative Remarks
8:10 Opening Remarks
Suzette Priola, Ph.D., Chairperson
8:20 Informational Presentation
Update
on BSE surveillance in the U.S., Lisa Ferguson, DVM, USDA
8:30 Topic
# 1 - Possible vCJD Risk from Investigational Coagulation Factor XI
Manufactured before 1998 from Plasma of Donors Residing in the United Kingdom
A. Introduction (10’), Mark Weinstein, Ph.D., OBRR, FDA
B.
Risk Assessment – U.K. plasma
derivatives
Risk assessment
methods and assumptions and U.K. actions based on risk assessment (40’),
Kate Soldan, Ph.D., and Anna Molesworth, MSc, U.K. Health Protection Agency
C. Risk assessment for U.K. FXI (45’), Steven. Anderson,
Ph.D., OBE, FDA
D. Current public health recommendations on management of
surgical instruments used on patients with TSE or TSE risk (10’), Lynne
Sehulster, Ph.D., CDC
10:15 Questions for
Speakers
10:25 Open Public
Hearing
10:40 Break
10:50 a.m. Committee Discussion and Vote
TSEAC AGENDA, February 8,
2005, page 2
11:30 Topic # 2 – Risk Assessment Models for Potential Risk of
Exposure to variant Creutzfeldt-Jakob Disease (vCJD) Agent in Plasma Products
A. Introduction – Rationale for risk assessments; question to
Committee (10’) Dorothy Scott, M.D., OBRR, FDA
B. Preliminary Risk Assessment – U.S.
1.
Potential TSE clearance steps
in U.S. products - FVIII, FIX, IGIV (10’), Dorothy Scott, M.D., OBRR, FDA
2.
Risk Assessment Model for
U.S. plasma derivatives (40’) Steve Anderson, Ph.D., OBE, FDA
12:30 p.m. Questions for Speakers
12:40 Lunch
1:40 Open Public Hearing
2:10 Committee Discussion and Vote
3:05 Break
3:15 Topic # 3 – Potential Deferral of Blood and
Plasma Donors for History of Transfusion in European Countries
A. Introduction (10’), Alan Williams, Ph.D., OBRR, FDA
B.
Epidemiology of vCJD in
France and risk assessments for blood and plasma derivatives (25’), Dr. Jean-Philippe Brandel, Neurologist, Epidemiosurveillance Network
C. Estimates of blood-borne vCJD risk in the U.K. and other
European populations (20’), Sheila M. Bird, M.A., Ph.D, Medical Research
Council Biostatistics Unit, Institute of Public Health, Cambridge University,
UK
D. Risks and benefits of deferring donors transfused in France
and other European countries: potential impact on blood and plasma supplies,
and presentation of questions for the committee (20’), Alan Williams,
Ph.D.
4:30 Open Public Hearing
4:50 Committee Discussion and Vote
5:35 p.m. Adjourn